Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Cancer: early-phase trial registry
147 of 338 indexed Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #20 of 28,707 conditions by registered trial count.
338 US clinical trials · 147 currently recruiting · #20 of 28,707 conditions by registered trial count
Ovarian Cancer: 338 US clinical trials tracked, 147 recruiting.
Ovarian Cancer is the subject of 338 registered US clinical trials on ClinicalTrials.gov, 147 of them currently open to new participants. 28 are in Phase 3-4 (later-stage) and 230 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition ovarian-cancer
OPEN 147 | RECR 43% | LATE 28 | EARLY 230 | RANK #20 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Cigarette Smoking (43% recruiting · 46 trials)
Ovarian Cancer lists 147 open slots (43% of 338 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Cancer is recruiting above its size-band peers.
147 of 338 indexed trials (43.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ovarian Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 31 of 338 trials (9.2%). 186 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Cancer enrolment sits around 86 participants.
Median target enrolment is 86 among the 323 trials that report a genuine target (sentinel values excluded). 172 of those (53.3%) plan for fewer than 100 participants.
-
Ovarian Cancer research is mostly interventional.
297 interventional and 41 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
338 total, page 4 of 7
Estrogen, Diet, Genetics and Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT00587886
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
Memorial Sloan Kettering Cancer Center
NCT02917798
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics
NCT05973487
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
AGO Study Group
NCT02828618
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4
NCT04140526
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Merck Sharp & Dohme
NCT05116189
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio
NCT04498117
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus
NCT03860272
Depression Treatment and Screening in Ovarian Cancer Patients
M.D. Anderson Cancer Center
NCT00515372
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
Susan Lutgendorf
NCT04533763
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT04180371
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
M.D. Anderson Cancer Center
NCT02043158
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Verastem
NCT04625270
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT01223248
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
AstraZeneca
NCT04421963
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03836352
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Hoffmann-La Roche
NCT04931342
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Xencor
NCT05032040
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
AstraZeneca
NCT01081951
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
NCT04553133
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Uswm CT
NCT04044859
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
NCT06483997
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure
NCT05572684
A Trial of Vigil for Participants With Ovarian Cancer
Gradalis
NCT02346747
Assessing the Time Demands of Cancer
Masonic Cancer Center, University of Minnesota
NCT05708703
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
M.D. Anderson Cancer Center
NCT01439659
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
NCT02873962
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
NCT05059522
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Uswm CT
NCT05601752
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono Research & Development Institute
NCT06433219
Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass
Southern Illinois University
NCT02109367
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
OncoC4
NCT05446298
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
NCT02571725
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Brown University
NCT03355976
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma
NCT05226507
Assessment of Paclitaxel-Induced Neuropathy
University of Chicago
NCT01953159
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
NCT02884648
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
Abramson Cancer Center at Penn Medicine
NCT06436248
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Beth Israel Deaconess Medical Center
NCT00799110
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 143 |
| Phase 2 | 87 |
| Phase 3 | 25 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Cancer page
338 registered trials, 147 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 147 Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Cancer condition card totals 338 registered trials; most-linked intervention Bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.